METTL3 and esophageal cancer: m6A modulators also reduce or exacerbate resistance to chemoradiotherapy in cancer patients.168 For example, targeting SNHG3/miR-186-5p reversed platinum treatment-induced elevated m6A levels by modulating METTL3 in esophageal cancer.529 m6A modification of FZD10 mRNA leads to PARPi resistance in BRCA-deficient epithelial ovarian cancer cells by upregulating the Wnt/β-catenin pathway.530 In addition, METTL3 can promote chemoresistance and radioresistance of pancreatic cancer cells.531 In terms of immunotherapy, two studies also revealed that m6A might be related to cancer immunotherapy.